Stock JBCHEPHARM J. B. CHEMICALS & PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials J. B. Chemicals & Pharmaceuticals Limited

Equities

JBCHEPHARM

INE572A01036

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:49 2024-04-29 am EDT 		5-day change 1st Jan Change
1,906 INR +2.27% Intraday chart for J. B. Chemicals & Pharmaceuticals Limited +6.72% +17.35%
Apr. 08 J. B. Chemicals & Pharmaceuticals Limited Appoints Akshay Tanna as A Non-Executive, Non-Independent Director CI
Mar. 22 J. B. Chemicals & Pharmaceuticals Limited Receives Order from Assessment Unit, Income Tax Department CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 28,853 39,286 96,881 121,735 152,503 289,291 - -
Enterprise Value (EV) 1 28,853 39,286 96,881 121,735 155,518 290,609 284,877 278,998
P/E ratio 15.3 x 14.9 x 21.6 x 31.6 x 37.7 x 48.4 x 38.7 x 34.5 x
Yield 1.39% 2.16% 1.32% 1.05% 0.9% 0.65% 0.77% 0.88%
Capitalization / Revenue 1.76 x 2.21 x 4.74 x 5.02 x 4.84 x 8.26 x 7.13 x 6.33 x
EV / Revenue 1.76 x 2.21 x 4.74 x 5.02 x 4.94 x 8.3 x 7.02 x 6.1 x
EV / EBITDA 9.45 x 10.4 x 17.3 x 22.4 x 22.4 x 31.8 x 26.2 x 22.2 x
EV / FCF 19.9 x 19.4 x 36.3 x 113 x 28.1 x 65.2 x 45.4 x 36.4 x
FCF Yield 5.02% 5.15% 2.76% 0.88% 3.56% 1.53% 2.2% 2.75%
Price to Book 2 x 2.82 x 5.35 x 5.7 x 6.15 x 8.86 x 7.46 x 6.19 x
Nbr of stocks (in thousands) 160,473 154,564 154,564 154,564 154,755 155,195 - -
Reference price 2 179.8 254.2 626.8 787.6 985.4 1,864 1,864 1,864
Announcement Date 5/21/19 6/25/20 6/14/21 5/26/22 5/24/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 16,432 17,747 20,425 24,242 31,493 35,014 40,582 45,702
EBITDA 1 3,054 3,776 5,604 5,435 6,958 9,148 10,886 12,594
EBIT 1 2,912 3,113 4,917 4,708 5,813 7,853 9,482 11,143
Operating Margin 17.72% 17.54% 24.08% 19.42% 18.46% 22.43% 23.37% 24.38%
Earnings before Tax (EBT) 1 2,870 3,489 5,969 5,049 5,552 7,716 9,533 11,434
Net income 1 1,940 2,720 4,480 3,854 4,098 5,640 7,062 8,489
Net margin 11.8% 15.33% 21.93% 15.9% 13.01% 16.11% 17.4% 18.58%
EPS 2 11.77 17.10 28.98 24.91 26.17 38.54 48.14 54.09
Free Cash Flow 1 1,447 2,024 2,670 1,073 5,530 4,460 6,274 7,671
FCF margin 8.81% 11.4% 13.07% 4.42% 17.56% 12.74% 15.46% 16.78%
FCF Conversion (EBITDA) 47.39% 53.61% 47.65% 19.74% 79.49% 48.75% 57.63% 60.9%
FCF Conversion (Net income) 74.62% 74.4% 59.61% 27.84% 134.94% 79.06% 88.84% 90.36%
Dividend per Share 2 2.500 5.500 8.250 8.250 8.875 12.20 14.37 16.31
Announcement Date 5/21/19 6/25/20 6/14/21 5/26/22 5/24/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 5,482 5,285 6,060 5,930 6,007 6,246 7,848 8,094 7,927 7,623 8,962 8,986 8,629 8,603
EBITDA 1 1,710 1,239 1,637 1,267 1,117 1,249 1,728 1,846 1,748 1,636 2,321 2,307 2,289 1,990
EBIT - - - - - - - - - - - - - -
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 - - - - - - - 1,489 1,412 1,225 1,943 1,949 1,919 1,584
Net income 1 1,541 1,006 1,189 977.5 838.9 848.4 1,050 1,111 1,061 876.3 1,423 1,409 1,413 1,201
Net margin 28.11% 19.04% 19.62% 16.48% 13.97% 13.58% 13.38% 13.72% 13.38% 11.5% 15.88% 15.68% 16.37% 13.96%
EPS 2 - - 7.690 6.315 5.410 5.480 - - 6.785 - 9.070 9.405 9.390 7.567
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 2/10/21 6/14/21 8/12/21 11/11/21 2/14/22 5/26/22 8/4/22 11/11/22 2/8/23 5/24/23 8/9/23 - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 3,015 1,319 - -
Net Cash position 1 - - - - - - 4,414 10,292
Leverage (Debt/EBITDA) - - - - 0.4333 x 0.1441 x - -
Free Cash Flow 1 1,447 2,024 2,670 1,073 5,530 4,460 6,274 7,671
ROE (net income / shareholders' equity) 13.3% 18.7% 27.6% 19.5% 17.8% 20.7% 21.8% 21.8%
ROA (Net income/ Total Assets) - - - - 13.3% 14% 16% 17%
Assets 1 - - - - 30,806 40,289 44,140 49,937
Book Value Per Share 2 89.80 90.20 117.0 138.0 160.0 210.0 250.0 301.0
Cash Flow per Share 2 - - - 11.00 40.40 47.70 51.40 59.60
Capex 1 483 730 478 629 726 2,085 855 880
Capex / Sales 2.94% 4.11% 2.34% 2.59% 2.3% 5.96% 2.11% 1.92%
Announcement Date 5/21/19 6/25/20 6/14/21 5/26/22 5/24/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for J. B. Chemicals & Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1,864 INR
Average target price
1,882 INR
Spread / Average Target
+0.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
J. B. CHEMICALS & PHARMACEUTICALS LIMITED Stock J. B. Chemicals & Pharmaceuticals Limited
+17.35% 3.47B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.86% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.78% 231B
NOVARTIS AG Stock Novartis AG
+5.23% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-8.75% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JBCHEPHARM Stock
  4. Financials J. B. Chemicals & Pharmaceuticals Limited